PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

PDS Biotechnology Corporation announced the reopening of recruitment in the National Cancer Institute-led Phase II clinical trial evaluating PDS0101 in combination with two investigational immune-modulating agents in advanced HPV cancers.